anti-platelet therapy. 4 Therefore, efficient platelet inhibition is crucial for the prevention of ST and other adverse cardiovascular events in these high risk-patients.
High post-interventional platelet reactivity (HPR) is a risk factor for ST and has been associated with ischemic cardiovascular events such as unstable angina, myocardial infarction, and cardiac death after PCI. [5] [6] [7] Of note, HPR has been shown to have a greater prognostic impact in ACS patients than in patients that undergo elective PCI. 8 Because of the low positive predictive value of HPR and the absence of large-scale randomized clinical trials supporting routine platelet function testing in all patients undergoing PCI, current guidelines suggest platelet function testing only for selected patients at high risk of a poor outcome after PCI. 9 Thus, we sought to investigate the prognostic relevance of platelet function testing in critically ill, high-risk cardiologic patients after cardiac arrest, or in cardiogenic shock. 
| METHODS

| Statistical analysis
Data are presented as mean ± standard deviation (SD). A P value < 0.05 were analyzed by Kaplan-Meier analysis, and differences were compared using the log-rank test. Receiver-operating characteristic (ROC) curves were generated to determine the discriminative power of WBIA (IBM® SPSS® Statistics, Version 21.0.0). The optimal cutoff point was calculated by determining the value with the greatest sum of sensitivity and specificity. (Tables 1 and 2 ).
The incidence of HPR to P2Y12 antagonists was 7.3% and the incidence of HPR to ASA was 3.9%. There were no significant differences between patients with or without HPR after platelet inhibition with regard to the incidence of OHCA, the duration of CPR, or therapeutic hypothermia. The only factors associated with a low response to antiplatelet therapy were a highly reduced left ventricular ejection fraction (LVEF) and hemodialysis (HPR to ASA: P = 0.014 for LVEF, P = 0.007 for dialysis; HPR to P2Y12 antagonists: P = 0.039 for dialysis). Five patients had HPR to both, ASA and P2Y12 antagonists after primary PCI, and two of these patients (40.0%) suffered an early ST within the first 30 days.
Clinical outcomes stratified by HPR are shown in Table 3 . An angiographically confirmed ST was diagnosed in 14 (3.9%) patients.
The rate of definite early STs was 19.2% in patients with HPR to P2Y12
antagonists and 1.2% in patients without HPR. Likewise, the incidence of early ST in patients with HPR to ASA was 21.4% versus 1.8% in patients without HPR. The overall incidence of definite ST was significantly higher in patients with HPR to ASA or HPR to P2Y12
antagonists (28.6% vs 2.9%; P < 0.001; and 19.2% vs 2.7%; P < 0.001; Figure 1 ). The same trend was observed in patients with possible or probable ST. In contrast, the incidence of late ST or recurrent myocardial infarction in untreated lesions was not associated with HPR to ASA or P2Y12 antagonists. Most ST occurred early after PCI at a median of 6 days (range 0-820 days). A total of 52.7% of the patients had a follow-up of more than 12 months (mean follow-up 547.6 ± 855.0 days). Intra-hospital mortality was significantly higher in patients with HPR to P2Y12 antagonists compared to patients without HPR (P = 0.012).
The rate of definitive ST was similar in patients receiving clopidogrel (10/265; 3.8%) compared to patients on ticagrelor (3/ 84; 3.6%). Also, the numeric difference between the incidence of HPR in patients receiving clopidogrel and patients receiving ticagrelor was not statistically significant (7.9% vs 4.8%). Prasugrel was rarely used.
One out of eight patients with prasugrel had HPR to P2Y12
antagonists ( HPR on ST was much less pronounced in stable coronary artery disease patients than in our study with critically ill patients.
ST is a complex multi-factorial process driven by the response to anti-platelet therapy but also by procedure and lesion related parameters and patient related risk factors. The most important anatomy and procedure related parameters are bifurcation lesions, stent under expansion, stent length, and residual stenosis. 13, 14 Individual risk factors which have been associated with increased incidence of ST in patients undergoing PCI include chronic kidney disease, diabetes, premature discontinuation of anti-platelet therapy, and low LVEF. 13, 15 In this study, hemodialysis and a highly reduced LVEF were the most important risk factors for HPR to anti-platelet therapy, suggesting that there might be an interaction between the response to anti-platelet therapy and patient related risk factors for ST. Nonetheless, the most important risk factors for ST in this analysis were young age and the use of tirofiban-both parameters not associated with HPR to antiplatelet therapy. The increased rate of ST in the tirofiban group should be interpreted carefully as it might rather reflect the extent of thrombus during primary PCI and does not imply that the use of GPIIa/IIIb inhibitors increases the risk for ST.
The incidence of ST varies greatly depending on the patient cohort and study design. In randomized trials evaluating drug eluting stents and in large observational studies with cardiopulmonary stable patients, the rate of early ST ranges from 0.5-1.1%. 16 In survivors of OHCA, ST occurs more frequently, depending on pre-hospital and peri-procedural treatment and the follow-up interval. A large retrospective study including 49 109 patients with OHCA due to MI
showed an overall incidence of ST after PCI of 4.7%. 17 This is in line with a definite ST rate of 3.9% in this study, although the rate of late and very late ST is possibly underestimated due to limited follow-up.
Past randomized clinical trials did not demonstrate a clear clinical benefit for personalized antiplatelet therapy based on platelet function testing. 18, 19 In this study, the administration of a second loading dose or, if possible, a switch to a more potent P2Y12 antagonist was at the discretion of the treating physician. However, there were limited Switching from ticagrelor to prasugrel in patients with HPR to ticagrelor has been associated with an unfavorable increase in platelet reactivity in patients with stable coronary disease. 20 This effect might be even more pronounced in patients with a critically hepatic perfusion or therapeutic hypothermia as prasugrel is an antithrombotic prodrug, which has to undergo a two-step enzymatic conversion into a biologically active metabolite. Therefore, no patients were switched from ticagrelor to prasugrel (or clopidogrel), even in the presence of HPR. Of note, the numeric lower rate of HPR in patients with ticagrelor compared to patients with clopidogrel did not translate into a lower rate of ST. The rate of definitive ST was similar in both groups. This emphasizes the impact of additional risk factors besides HPR like coagulation abnormalities, inflammation, hypothermia, renal insufficiency, gastro-esophageal reflux, and heart failure in these critically ill patients.
| Study limitations
The present study has several limitations. Major limitations are the retrospective study design and the limited follow-up data. Only half of the patients had a follow-up of more than 365 days, potentially leading to an underestimation of the rate of late and very late ST as well as recurrent type 1 and 2 myocardial infarctions. Therefore, the focus of this analysis was on early ST. In addition, we included only definite, angiographically confirmed ST into the primary analyses, which also might have added to the underestimation of the actual incidence of ST.
Accordingly, estimates of late ST rates are less precise, and should be interpreted carefully.
| CONCLUSIONS
The overall diagnostic performance of platelet function testing for ST in patients after OHCA or cardiogenic shock was moderate. However, considering the multifactorial etiology of ST, it might be far-fetched to expect a one-time blood test to reliably predict ST. Nonetheless, the positive predictive value and the overall accuracy of WBIA were low and limit its value as a routine screening procedure for ST. Therefore, HPR might be rather seen as a prognostic tool to identify critically ill patients at high risk for ST. 
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